BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cappella Medical Devices Ltd Receives Regulatory Approval in India to Market its Proprietary Sideguard® Technology Platform


3/5/2012 7:12:45 AM

GALWAY, Ireland--(BUSINESS WIRE)--Cappella Medical Devices Ltd (Cappella), the world’s leading cardiology technology company is pleased to announce that it has received regulatory approval in India for its flagship Sideguard® Coronary Stent system. Sideguard is widely recognized for its superior outcomes in treating patients percutaneously for complex and bifurcated lesions.

Up to 30% of all PCI’s [Percutaneous Coronary Interventions] include bifurcation disease. However, a gold standard for therapy involving such lesions does not yet exist. The Sideguard incorporates Cappella’s proprietary stent design and balloon delivery system, offering the interventional cardiologist a solution that, for the first time, provides ostial protection and side branch preservation, thereby enabling enhanced care for patients across a wide range of bifurcation lesions.

David Blossom, VP of Commercial Operations for Cappella said, “This regulatory approval in India represents an important milestone for Cappella Medical. Treating bifurcation disease has always been a challenge for physicians due to the complex anatomy of the coronary sidebranch and the inability of main vessel and work horse stents to address and protect the unique nature of such vasculature.” He added, “Now, clinicians in India, as in a number of other markets, will be able to use Cappella’s Sideguard system, a technology dedicated to bifurcation disease that scaffolds the ostium reducing plaque and carina shift while preserving the sidebranch. India is an important growing, yet underserved, market and Cappella looks forward to introducing its device and technology to clinicians throughout the country.”

The Cappella Sideguard system is currently CE mark approved and is being distributed throughout Europe, South America, and Canada.

About Cappella

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) and peripheral artery disease (PAD) focused on its flagship Sideguard technology platform. Cappella’s Sideguard® coronary sidebranch technology offers clinicians a straightforward, effective, and easy to use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift. The Sideguard delivery system features a proprietary split-sheath, balloon released, technology that ensures precise placement on the ostial borderline. The Sideguard self-expanding, nitinol, stent promotes continuous wall apposition and positive remodelling and its unique trumpet-shaped design conforms to varying characteristics of the sidebranch ostium. The Cappella Sideguard system is currently CE mark approved and is being distributed throughout Europe, South America, and Canada. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, please visit the Cappella Medical Systems website at www.cappella-med.com.

Contacts

Cappella Medical Devices Ltd

David Blossom, +353 91 758939

Dblossom@cappella.ie


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->